MUSCLE CELLS are primary targets for insulin action (5) . Consequently, there have,been numerous reports of insulin effects on diverse muscle tissues (9, 11, 13, 19, 28, 33) . Studies of muscle cells in culture utilized either whole-muscle explants (13, 19, 33) , dissociated monolayers of primary cells (ll) , or various muscle cell lines (1, 9, 28) . These in vitro studies were limited to nonhuman cells, since no human muscle cell lines exist, and the amount of human muscle that -can be obtained via biopsy procedures is quite limited (4, 18) .
Recently, a method has been developed to isolate and grow pure populations of human muscle cells in quantity (2, 3) . This procedure capitalizes on the presence in biopsy samples of satellite cells, precursor muscle cells positioned adjacent to mature muscle fibers that are capable of proliferating both in vivo and in vitro. By isolating pure clones of these cells, one can circumvent the problem of contaminating nonmyogenic cells overgrowing the muscle cells in long-term cultures. Sufficient material for studies can be obtained by this procedure, since, on average, 1012 cells can be obtained from a single myoblast isolated from postnatal muscle tissue. Upon exposure to specific culture conditions, these cells can be induced to differentiate into myotubes with a resulting marked increase in the synthesis of muscle specific contractile and membrane proteins (2,3). Thus these methods provide a means for obtaining sufficient muscle cells from patients for analyses of insulin function in the cells of a tissue that is a major target for the action of this hormone. Such a system could be utilized to study the details of the biochemical and molecular defects in patients with various genetic conditions associated with insulin resistance (20, 26, 29) . As a first step toward such studies, this paper presents an analysis of the receptors for and responses to insulin in cultured human muscle cells. In addition, since insulin is a member of a family of regulatory polypeptides, which include the insulinlike growth factors, we have analyzed the same cells for their receptors and responses to two other molecules, insulinlike growth factor I (IGF-I) and insulinlike growth factor II (IGF-II). IGF-I and II share -50% sequence homology with insulin, display a similar spectrum of biological activities to that of insulin, and can interact to some extent with the insulin receptor (21, 34) . In addition, these two molecules have their own distinct receptors. The receptor for IGF-I is structurally similar to that of insulin and insulin interacts with it with weak affinity (21) . In contrast, the receptor for IGF-II is structurally quite distinct from both the insulin and IGF-I receptors and does not bind insulin (21) . However, both IGF can bind to the insulin receptor with weak affinity (21) .
To help determine whether a particular physiological response to insulin or IGF was mediated via its respective receptor, two different monoclonal antibodies were utilized. One of these antibodies (MC51) preferentially inhibits insulin binding and action through its own receptor (22, 23) . The second antibody (a-IR3) inhibits IGF-I binding and action through its receptor (8, 30 after plating, at which time they were either used as myoblasts or exposed to fusion medium to differentiate and form myotubes. Myotube cultures typically initiated fusion within 24 h in fusion medium and were used within 3-4 days, by which time 70% of nuclei were contained in myotubes.
Binding studies. 1251-insulin, 1251-IGF-I and 1251-IGF-II were prepared as previously described'by a modified chloramine-T method to specific activities of 120, 100, and 100 &i/pg, respectively (23) . For the IGF-II binding studies included in this report, MSA 111-2, which is a single component on ,high-performance liquid chromatography (P. Nissley, Personal Communication), was utilized in the iodinations. To assay nonspecific binding of 1251-IGF-II, a mixture of equal parts of unlabeled ligands IGF-I and IGF-II was utilized. Unlabeled insulin and IGF-I were used to determine nonspecific binding of their respective labeled ligands. Cells were washed with 2 ml of Tris-buffered saline (pH 7.6) and incubated in 1 ml of 50 mM HEPES-buffered saline (pH 7.8) containing 1% bovine serum albumin. Incubations were performed for 16 h at 4°C with 60-80 pM labeled ligand in the presence or absence of the indicated concentrations of competing ligands. Binding was terminated by rapid washing of the cells with ice-cold Tris-buffered saline (pH 7.8). After three washes, the cells were solubilized with 0.04% sodium dodecyl sulfate, counted, and the protein measured. Results are expressed as percent total counts bound per protein. For myoblasts and myotubes, the results were normalized to 50 and 70 pg protein, respectively (these were the average amounts of protein present per dish for the 2 cell types). ' In this paper, the term IGF-II is used to include both human IGF-II and MSA. which is the rat form of IGF-II (14.17).
MAIB uptuke. Amino acid uptake was monitored by the use of the nonmetabolizable amino acid analogue MAIB by a modification of the method described by others (6, 11) . In brief, cells were washed twice with buffer (140 mM NaCl, 2.7 mM KCl, 0.9 mM CaC12, 1.47 mM KH2P04, 8.06 mM Na2HP04, and 0.49 mM MgC12, pH 7.4) containing 0.1% bovine serum albumin and 5 mM glucose. Cells were then incubated for 3 h at 37°C with the indicated concentration of hormone in the above buffer with 2% bovine serum albumin and 20 mM glucose. In the experiments with the antibodies, cells were preincubated with antibody for 30 min before the addition of hormone. Amino acid uptake was measured by addition of 3 PM a-[ methyl-3H]aminoisobutyric acid (0.2 &i/ml).
After 10 min at 37"C, the cells were rapidly washed three times with ice-cold buffer, solubilized in 0.04% sodium dodecyl sulfate, counted, and protein determined. Uptake is expressed as the percentage of total counts taken up per unit protein (either 100 or 150 pg protein for myoblasts or myotubes, respectively).
Deoxyglucose uptake. Regulation of glucose uptake was performed as described for MAIB uptake except that glucose .was omitted from the buffer and 30 PM [3H]-deoxyglucose (30 Ci/mol) were added to the cells 10 min after the addition of insulin. Fifteen minutes after the addition of deoxyglucose, a period when uptake was linearly dependent on time, the cells were rapidly washed and processed as described above.
RESULTS
Hormone binding studies. Cultured human myoblasts and myotubes were found to specifically bind 1251-IGF-I and 1251-IGF-II (Fig. 1) . The amount of IGF-II specifically bound (2.9% of the total) was approximately three times that of IGF-I, and the amounts of both hormones bound did not change after differentiation (Fig. 1, C insulin increased after differentiation; specific binding of 1251-insulin to myoblasts was below the limits of detection, whereas 0.28% of the 1251-insulin was specifically bound to myotubes (Fig. 1, A and B) . Binding of 12?-insulin to myotubes was shown to be via the insulin receptor, since insulin at 3 nM half-maximally inhibited binding (Fig. lB) , a potency similar to that of other tissues (20) . 1251-IGF-I was primarily bound to an IGF-I receptor, since IGF-I at 0.3 nM half-maximally inhibited binding (Fig. 1, C and D) , whereas inhibition of IGF-I binding by insulin required micromolar concentrations. In contrast, 1251-IGF-II binding was not inhibited even at very high concentrations (10 PM) of insulin indicating that this ligand was binding to the IGF-II receptor (21) .
The identification of which receptors were binding labeled ligand was confirmed by the use of monoclonal antibodies. A monoclonal antibody to the insulin receptor, MC51, was found to inhibit 1251-insulin binding to myotubes with a half-maximal effect at 100 nM (Fig. 2) . In contrast, this antibody did not inhibit 1251-IGF-I or IGF-II binding to either myoblasts or myotubes.
A monoclonal antibody to the IGF-I receptor, ~1R3, inhibited IGF-I binding to both myoblasts and myotubes (Fig. 2) . However, this antibody at 100 nM only inhibited -6O-75% of the specific binding of 1251-IGF-I. In contrast, this antibody did not significantly inhibit the binding of 1251-insulin or IGF-II to the muscle cells at concen- trations up to 100 nM.
Biological responses. The biological effects of insulin on the,myoblasts and myotubes were also studied. Insulin was found to stimulate deoxyglucose uptake in myotubes but not myoblasts (data not shown). A half-maximal response was observed with 0.8 nM insulin, a value similar to that observed for muscle cultures of other species (13, 33) .
The effects of insulin and IGF-I and -11 on the uptake of the nonmetabolizable amino acid analogue, MAIB, were then investigated because these hormones were previously shown to regulate this metabolic response in rodent muscle cells (6, 11, 32) . IGF-I and -11 were found to be almost equipotent stimulators of this response in myoblasts (Fig. 3A) ; responsescould be detected with as little as 0.1 nM hormone. In contrast, myotubes were considerably more responsive to IGF-I than to IGF-II (Fig. 3B) . Insulin stimulation of MAIB uptake, in both myoblasts and myotubes, required concentrations lo-100 times greater than that for IGF-I (Fig. 3) , and the maximal effect of insulin was also less than that with IGF-I.
To determine which receptors were mediating the stimulation of MAIB uptake in these cells, the monoclonal antibodies were tested for their ability to inhibit the responses of these cells to insulin and the IGFs. Monoclonal antibody MC51, the antibody that preferentially recognizes the insulin receptor, inhibited the insulin response of both myoblasts and myotubes in a dose-dependent fashion with a maximal inhibition of 40% at 1 PM (Fig. 4) . In contrast, this antibody had no effect on the response of either cell type to IGF-I (Fig.  4) or IGF-II (data not shown). a-IR3, the monoclonal antibody that specifically recognizes the IGF-I receptor, was found to inhibit by -50% the response of myoblasts to either IGF-I or -11 (Fig. 5A ). This antibody was more potent at inhibiting the responses of myotubes to IGF-I and -11, inhibiting these responses by -90% (Fig. 5B ). This antibody also partly inhibited (by -30%) the response of the two types of muscle cells to insulin. the biological responses of both the myoblasts and myotubes to insulin. First, insulin was found to stimulate uptake of both deoxyglucose and amino acids at nanomolar concentrations, concentrations of insulin that would result in interactions predominantly with the insulin receptor. Second, the stimulation by insulin of both amino acid uptake (Fig. 4) and glucose uptake (data not shown) was inhibited by the monoclonal antibody, MC51, which interacts preferentially with the insulin receptor. Finally, the monoclonal antibody that interacts preferentially with the IGF-I receptor, a-IR3, only inhibited the insulin responses by -30% (Fig. 5) . These results suggest that the insulin response of the muscle cells is mediated in part by the insulin and in part by the IGF-I receptor. A similar hypothesis has been proposed for insulin's actions on a human hepatoma cell line (31) . 
DISCUSSION
In the present studies we have analyzed cultured human muscle cells for their receptors and responses to insulin and insulinlike growth factors. Specific receptors for each of these molecules were demonstrated in these cells (Fig. 1) . Furthermore, an increase in insulin receptors was observed after differentiation of the cells from myoblasts to myotubes (Fig. 1) . Similar results have been reported for various rodent cell lines (1, 6, 9, 10, 28) . The insulin receptor in myotubes was found to be similar antigenically to that in other tissues, since a monoclonal antibody (MC51) to the insulin receptor was found to inhibit insulin binding to the muscle receptor ( Fig. 1) with about the same potency as -that observed with several other human tissues (24) .
The presence of three different receptors (insulin, IGF-I, and IGF-II) with overlapping specificities complicates the assignment of a particular response to a particular receptor. The present studies, however, strongly support a role for the insulin receptor in at least partly mediating
The finding that the responses to insulin of myoblasts as well as myotubes were mediated by the insulin receptor may appear surprising, since no specific insulin receptors were detected on myoblasts in our binding assays (Fig.  1) . However, the present studies would have been unable to detect levels of receptors in the myoblasts five times less than that found for myotubes. Thus it is likely that myoblasts also contain insulin receptors that are responsible for partly mediating the biological responses to this hormone.
As has previously been reported for nonhuman muscle cells (1, 6, 7, 9-11, 15, 27, 32) , the insulinlike growth factors appear to stimulate a biological response in cultured human muscle cells by interacting with IGF receptors. First, these hormones were capable of stimulating a biological response at concentrations that would be unlikely to interact significantly with the insulin receptor (Fig. 3) . Second, the monoclonal antibody (MC5l) to the insulin receptor did not inhibit the responses of the muscle cells to the IGF (Fig. 4) . Finally, the monoclonal antibody to the IGF-I receptor (cw-IR3) did inhibit the responses of the cells to both IGF (, Fig. 5 ). The biological effects of both IGF on the myoblasts may in part be mediated by the IGF-I receptor and in part by the IGF-II receptor, since the monoclonal antibody to the IGF-I receptor only inhibited these responses by ~50% (Fig.  5A ). Alternatively, it is possible that there is another type of IGF-I receptor that is present in myoblasts and that is not recognized by cw-IR3. Evidence for multiple types of IGF-I receptors has been presented (12, 16, 25) . In contrast to the results with myoblasts, cu-IR3 was capable of inhibiting the responses of myotubes by 80. 90%, indicating that the IGF-I receptor was predominantly mediating the responses to both IGF in myotubes. This conclusion is also supported by the finding that IGF-I is more potent than IGF-II in stimulating a biological response in myotubes but not in myoblasts. , .
In summary, the present studies demonstrate that cultured human muscle cells have specific receptors and responses to insulin and insulinlike growth factors. The ability to obtain such muscle cells from patients with various genetic disorders should allow studies of the biochemical and molecular defects that give rise to insulin resistance in these patients.
